GOSS - Gossamer Bio, Inc.
| Previous Close | 22.54 |
| Open | 22.68 |
| Bid | 20.08 x 1400 |
| Ask | 0.00 x 800 |
| Day's Range | 22.00 - 23.20 |
| 52 Week Range | 14.49 - 25.06 |
| Volume | 418,069 |
| Avg. Volume | 556,253 |
| Market Cap | 1.403B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.98 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.33 |
- Business Wire
Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
- Business Wire
Gossamer Bio Announces Third Quarter 2019 Financial Results
– Clinical programs on track for multiple topline data releases in 2020 –
- Business Wire
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamer’s investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.
- Business Wire
Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company’s inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension , have been accepted for presentation at the American ...
- Business Wire
Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’s oral DP2 antagonist for the treatment of asthma and allergic disease, have been accepted for presentation at the American College ...
- Business Wire
Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting
- First-in-human Phase 1/2 trial of GB1275 to be featured in trial-in-progress poster -
- Simply Wall St.
Do Directors Own Gossamer Bio, Inc. (NASDAQ:GOSS) Shares?
Every investor in Gossamer Bio, Inc. (NASDAQ:GOSS) should be aware of the most powerful shareholder groups...
- Business Wire
Gossamer Bio to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 12, 2019
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2019 financial results on Tuesday, November 12, 2019.
- GuruFocus.com
Weekly CEO Buys Highlight
Insiders invest in Gossamer Bio, Heron Therapeutics and Athenex Continue reading...
- GuruFocus.com
Seth Klarman Further Increases Translate Bio Stake
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- Zacks
Implied Volatility Surging for Gossamer Bio (GOSS) Stock Options
Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.
- GuruFocus.com
Seth Klarman's Small Biotech Holdings
A look at some of the guru's smaller, overlooked positions Continue reading...
Motley FoolGossamer Bio, Inc. (GOSS) Q2 2019 Earnings Call Transcript
GOSS earnings call for the period ending June 30, 2019.
- Simply Wall St.
Read This Before Selling Gossamer Bio, Inc. (NASDAQ:GOSS) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
GuruFocus.comSeth Klarman's Favorite Biotech Positions
Some ideas from Baupost's pharmaceutical portfolio
GuruFocus.comSeth Klarman Introduces 7 New Positions in 1st Quarter
Baupost’s new positions include companies formed by Disney-Fox merger
Motley FoolGossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript
GOSS earnings call for the period ending March 31, 2019.
- Associated Press
Gossamer Bio: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 90 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment ...
- Business Wire
Gossamer Bio Announces First Quarter 2019 Financial Results
– Multiple trial initiations and data readouts expected in the next 12 months –
